| Characteristic . | EGFR . | EGFR . | P-value . | |
|---|---|---|---|---|
| Mutant . | Wild-type . | |||
| n = 192 (%) . | n = 187 (%) . | |||
| Median age (years) | Range | 69 (26–88) | 67 (37–87) | 0.103 |
| Sex | Male | 67 (35) | 118 (63) | <0.001 |
| Smoking history | Ex- or current | 55 (29) | 125 (67) | <0.001 |
| Never | 137 (71) | 62 (33) | ||
| Serum CEA | >5 mg/dl | 33 (17) | 45 (24) | 0.101 |
| Median FEV1.0 | l (range) | 2.1 (0.8–3.9) | 2.2 (1.0–5.0) | 0.426 |
| Procedure | Lobectomy | 175 (91) | 170 (91) | 1.000 |
| Segmentectomy | 12 (6) | 8 (4) | Lobar vs sublobar | |
| Wedge resection | 5 (3) | 9 (5) | ||
| Pathological stage | IA | 115 (60) | 91(49) | 0.159 |
| IB | 34 (18) | 42 (22) | I vs II more | |
| II | 16 (8) | 27 (14) | ||
| III | 23 (12) | 20 (11) | ||
| IV | 4 (2) | 7 (4) | ||
| WHO classification | AIS | 8 (4) | 17 (9) | 0.923 |
| MIA | 18 (9) | 9 (5) | IA vs others | |
| IA | 166 (87) | 161 (86) | ||
| Pleural invasion | Present | 34 (18) | 50 (27) | 0.036 |
| Vascular invasion | Present | 44 (23) | 51 (27) | 0.345 |
| Lymphatic permeation | Present | 57 (30) | 63 (34) | 0.442 |
| Adjuvant therapy | Not performed | 141 (73) | 132 (71) | 0.568 |
| Platinum double | 23 (12) | 24 (13) | Not vs others | |
| Oral drugs | 26 (14) | 27 (14) | ||
| Others | 2 (1) | 4 (2) | ||
| EGFR mutation | Exon21 L858R | 102 (53) | NA | |
| Exon19 del | 68 (35) | NA | ||
| Exon20 T790M | 11 (6)a | NA | ||
| Others | 16 (8) | NA | ||
| EGFR–TKI | Administered | 39 (20) | 10 (5) | <0.001 |
| Characteristic . | EGFR . | EGFR . | P-value . | |
|---|---|---|---|---|
| Mutant . | Wild-type . | |||
| n = 192 (%) . | n = 187 (%) . | |||
| Median age (years) | Range | 69 (26–88) | 67 (37–87) | 0.103 |
| Sex | Male | 67 (35) | 118 (63) | <0.001 |
| Smoking history | Ex- or current | 55 (29) | 125 (67) | <0.001 |
| Never | 137 (71) | 62 (33) | ||
| Serum CEA | >5 mg/dl | 33 (17) | 45 (24) | 0.101 |
| Median FEV1.0 | l (range) | 2.1 (0.8–3.9) | 2.2 (1.0–5.0) | 0.426 |
| Procedure | Lobectomy | 175 (91) | 170 (91) | 1.000 |
| Segmentectomy | 12 (6) | 8 (4) | Lobar vs sublobar | |
| Wedge resection | 5 (3) | 9 (5) | ||
| Pathological stage | IA | 115 (60) | 91(49) | 0.159 |
| IB | 34 (18) | 42 (22) | I vs II more | |
| II | 16 (8) | 27 (14) | ||
| III | 23 (12) | 20 (11) | ||
| IV | 4 (2) | 7 (4) | ||
| WHO classification | AIS | 8 (4) | 17 (9) | 0.923 |
| MIA | 18 (9) | 9 (5) | IA vs others | |
| IA | 166 (87) | 161 (86) | ||
| Pleural invasion | Present | 34 (18) | 50 (27) | 0.036 |
| Vascular invasion | Present | 44 (23) | 51 (27) | 0.345 |
| Lymphatic permeation | Present | 57 (30) | 63 (34) | 0.442 |
| Adjuvant therapy | Not performed | 141 (73) | 132 (71) | 0.568 |
| Platinum double | 23 (12) | 24 (13) | Not vs others | |
| Oral drugs | 26 (14) | 27 (14) | ||
| Others | 2 (1) | 4 (2) | ||
| EGFR mutation | Exon21 L858R | 102 (53) | NA | |
| Exon19 del | 68 (35) | NA | ||
| Exon20 T790M | 11 (6)a | NA | ||
| Others | 16 (8) | NA | ||
| EGFR–TKI | Administered | 39 (20) | 10 (5) | <0.001 |
CEA: carcinoembryonic antigen; NA: not available; EGFR: epidermal growth factor receptor; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; TKI: tyrosine kinase inhibitor.
aFive patients had both exon21 L858R and exon20 T790M.
| Characteristic . | EGFR . | EGFR . | P-value . | |
|---|---|---|---|---|
| Mutant . | Wild-type . | |||
| n = 192 (%) . | n = 187 (%) . | |||
| Median age (years) | Range | 69 (26–88) | 67 (37–87) | 0.103 |
| Sex | Male | 67 (35) | 118 (63) | <0.001 |
| Smoking history | Ex- or current | 55 (29) | 125 (67) | <0.001 |
| Never | 137 (71) | 62 (33) | ||
| Serum CEA | >5 mg/dl | 33 (17) | 45 (24) | 0.101 |
| Median FEV1.0 | l (range) | 2.1 (0.8–3.9) | 2.2 (1.0–5.0) | 0.426 |
| Procedure | Lobectomy | 175 (91) | 170 (91) | 1.000 |
| Segmentectomy | 12 (6) | 8 (4) | Lobar vs sublobar | |
| Wedge resection | 5 (3) | 9 (5) | ||
| Pathological stage | IA | 115 (60) | 91(49) | 0.159 |
| IB | 34 (18) | 42 (22) | I vs II more | |
| II | 16 (8) | 27 (14) | ||
| III | 23 (12) | 20 (11) | ||
| IV | 4 (2) | 7 (4) | ||
| WHO classification | AIS | 8 (4) | 17 (9) | 0.923 |
| MIA | 18 (9) | 9 (5) | IA vs others | |
| IA | 166 (87) | 161 (86) | ||
| Pleural invasion | Present | 34 (18) | 50 (27) | 0.036 |
| Vascular invasion | Present | 44 (23) | 51 (27) | 0.345 |
| Lymphatic permeation | Present | 57 (30) | 63 (34) | 0.442 |
| Adjuvant therapy | Not performed | 141 (73) | 132 (71) | 0.568 |
| Platinum double | 23 (12) | 24 (13) | Not vs others | |
| Oral drugs | 26 (14) | 27 (14) | ||
| Others | 2 (1) | 4 (2) | ||
| EGFR mutation | Exon21 L858R | 102 (53) | NA | |
| Exon19 del | 68 (35) | NA | ||
| Exon20 T790M | 11 (6)a | NA | ||
| Others | 16 (8) | NA | ||
| EGFR–TKI | Administered | 39 (20) | 10 (5) | <0.001 |
| Characteristic . | EGFR . | EGFR . | P-value . | |
|---|---|---|---|---|
| Mutant . | Wild-type . | |||
| n = 192 (%) . | n = 187 (%) . | |||
| Median age (years) | Range | 69 (26–88) | 67 (37–87) | 0.103 |
| Sex | Male | 67 (35) | 118 (63) | <0.001 |
| Smoking history | Ex- or current | 55 (29) | 125 (67) | <0.001 |
| Never | 137 (71) | 62 (33) | ||
| Serum CEA | >5 mg/dl | 33 (17) | 45 (24) | 0.101 |
| Median FEV1.0 | l (range) | 2.1 (0.8–3.9) | 2.2 (1.0–5.0) | 0.426 |
| Procedure | Lobectomy | 175 (91) | 170 (91) | 1.000 |
| Segmentectomy | 12 (6) | 8 (4) | Lobar vs sublobar | |
| Wedge resection | 5 (3) | 9 (5) | ||
| Pathological stage | IA | 115 (60) | 91(49) | 0.159 |
| IB | 34 (18) | 42 (22) | I vs II more | |
| II | 16 (8) | 27 (14) | ||
| III | 23 (12) | 20 (11) | ||
| IV | 4 (2) | 7 (4) | ||
| WHO classification | AIS | 8 (4) | 17 (9) | 0.923 |
| MIA | 18 (9) | 9 (5) | IA vs others | |
| IA | 166 (87) | 161 (86) | ||
| Pleural invasion | Present | 34 (18) | 50 (27) | 0.036 |
| Vascular invasion | Present | 44 (23) | 51 (27) | 0.345 |
| Lymphatic permeation | Present | 57 (30) | 63 (34) | 0.442 |
| Adjuvant therapy | Not performed | 141 (73) | 132 (71) | 0.568 |
| Platinum double | 23 (12) | 24 (13) | Not vs others | |
| Oral drugs | 26 (14) | 27 (14) | ||
| Others | 2 (1) | 4 (2) | ||
| EGFR mutation | Exon21 L858R | 102 (53) | NA | |
| Exon19 del | 68 (35) | NA | ||
| Exon20 T790M | 11 (6)a | NA | ||
| Others | 16 (8) | NA | ||
| EGFR–TKI | Administered | 39 (20) | 10 (5) | <0.001 |
CEA: carcinoembryonic antigen; NA: not available; EGFR: epidermal growth factor receptor; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; TKI: tyrosine kinase inhibitor.
aFive patients had both exon21 L858R and exon20 T790M.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
